Tang Capital Management LLC Acquires Shares of 300,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)

Tang Capital Management LLC purchased a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 300,000 shares of the company's stock, valued at approximately $3,309,000. Tang Capital Management LLC owned about 0.57% of Stoke Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. RTW Investments LP increased its holdings in Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after purchasing an additional 471,240 shares during the period. Baker BROS. Advisors LP grew its position in shares of Stoke Therapeutics by 6.1% in the 4th quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company's stock valued at $51,111,000 after buying an additional 265,395 shares during the last quarter. Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $35,001,000. Assenagon Asset Management S.A. raised its position in shares of Stoke Therapeutics by 2.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company's stock worth $14,901,000 after acquiring an additional 38,446 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Stoke Therapeutics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 877,095 shares of the company's stock worth $9,677,000 after acquiring an additional 6,264 shares during the last quarter.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This trade represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares of the company's stock, valued at $554,550.54. This trade represents a 5.72% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 over the last ninety days. 11.30% of the stock is owned by corporate insiders.

Stoke Therapeutics Trading Up 0.4%

NASDAQ STOK traded up $0.04 during trading hours on Friday, hitting $9.54. 141,613 shares of the company's stock were exchanged, compared to its average volume of 709,179. The firm has a market cap of $520.91 million, a price-to-earnings ratio of -4.54 and a beta of 1.20. The stock has a 50-day simple moving average of $8.25 and a 200 day simple moving average of $9.89. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

STOK has been the topic of several analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright dropped their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday, May 14th. Finally, Chardan Capital reiterated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $23.20.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.